Neurologix, Inc., a development stage company, engages in the research and development of proprietary treatments for disorders of the brain and central nervous system, using gene transfer and other therapies. The company’s development activities are focused on gene transfer for treating Parkinson’s disease. Its technology, referred to as ‘NLX,’ is in the clinical development stages, was tested in a Phase 1 and Phase 2 clinical trials to treat Parkinson’s disease. The company intends to continue to develop therapies to treat other neurodegenerative and metabolic disorders, including clinical testing for its therapy relating to Huntington’s disease. Agreements The company has a license agreement with Aegera Therapeutics Inc. whereby it was granted a license for the worldwide rights, excluding China, for the use of dXIAP for therapeutic or prophylactic purposes in the treatment of Huntington’s disease. In 2009, the company entered into a license agreement with Cornell University (Cornell), whereby Cornell granted it a license for the worldwide use of certain patents for the development of products and methods for the treatment of psychiatric conditions. History Neurologix, Inc. was founded in 1999.
(NRGXQ:OTC Markets Group Inc - No Information)
One Bridge Plaza
Fort Lee, NJ 07024
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for NRGXQ.|
|View Industry Companies|
|No financial data is available for NRGXQ.|
Sponsored Financial Commentaries
To contact NEUROLOGIX INC, please visit www.neurologix.net. Company data is provided by Capital IQ. Please use this form to report any data issues.